[53] Terminal deoxynucleotidyl

[53] Terminal deoxynucleotidyl Ceritinib concentration transferase (TdT) and DNA Pol μ further diversify these junctional sequences by catalysing the addition of non-templated nucleotides (N-nucleotides) to the coding ends.[54] The junctional diversification can expand the diversity upto 1011 from the earlier 106 through the combinatorial diversification. Alternative outcomes of

V(D)J recombination reported were ‘hybrid joint’ and ‘open-shut joint’. During the formation of ‘hybrid joint’, the coding end of one subexon is joined to the signal end of another following the initial cleavage step of V(D)J recombination. In certain cases, the original pair of coding and signal ends, which was separated during the RAG cleavage phase, rejoins leading to formation of an ‘open-shut joint’.[55] When there are no modifications at the joints, ‘open-shut joints’ are hard to detect. The released signal ends may non-specifically attack double-stranded DNA leading to transposition.[55] The antigen receptors are further modified

by two processes, namely class switch recombination (CSR) and somatic hypermutation (SHM). The CSR refers to the rearrangements of the constant regions of antigen receptors upon encountering an antigen. This further expands the variability in the constant region following rearrangement at the variable region. The CSR replaces the expression from Cμ to Cγ, Cε or Cα, resulting in the switching of immunoglobulin isotype from IgM to IgG, IgE,

or IgA without changing the antigen specificity (Fig. 3).[56] The immunoglobulin CH locus comprises an array of CH genes, flanked by a switch (S) region selleck inhibitor at its 5′ region. The CSR takes place between two S regions, resulting in the loop-out deletion of the intervening DNA segments as circular DNA [57] (Fig. 3). The SHM refers to the random genetic mutations that occur in the B cells CYTH4 (and not T cells) at certain hotspots in the antigen-binding regions following an antigen encounter and results in the increased affinity of the receptor to the antigen.[58] As a result of this, a fraction of the antibodies possessing low-affinity receptors to the defined antigen, further increase their affinity and undergo expansion. The SHM takes place in the V region of both H and L chain genes (VL/H), introducing a million times more point mutations than the genome-wide background leading to the generation of high-affinity antibodies. Hence, CSR and SHM act on entirely different targets, i.e. CH and VL/H, respectively. Therefore, it was believed that these two processes were regulated differently. However, recently, it has been shown that the same enzyme, the activation-induced cytidine deaminase initiates both CSR and SHM in mice and humans.[57, 59, 60] Murine RAG1 comprises 1040 amino acids. The ‘core region’ of RAG1 (cRAG1) consisting of amino acids 384–1008, is essential for all activities in vivo and in vitro.[61, 62] RAG1 exists as a homodimer in solution.

Comments are closed.